June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 03, 2025

FDA Grants Breakthrough Status to Shield Test

The methylation-based blood assay is designed for screening multiple cancer types.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

Careers Uncovered: Happy in Hematopathology

Kamran Mirza, Professor of Pathology and Director of the Division of Education Programs, talks pulling back the curtain on pathology, humbling experiences, and patient connections

The Pathologist

May 27, 2025

Mucous Membrane Pemphigoid Linked to Higher Skin Cancer Risk

Investigators found that patients with mucous membrane pemphigoid, especially those with severe disease, face increased risks of squamous and basal cell carcinomas.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 21, 2025

Diabetes Drug TZDs May Curb Prostate Cancer

Older type 2 diabetes drugs that target PPAR-gamma may slow prostate cancer progression.

Reuters

May 20, 2025

Clinical Trials Missing in Half of AI Tools

Researchers analyzed FDA-approved AI-enabled medical devices and reported that clinical performance and subgroup data were frequently missing.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant